PCM
NEPH icon

Prelude Capital Management’s Nephros NEPH Stock Holding History

Prelude Capital Management’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.8K Sell
13,680
-1,500
-10% -$5.99K ﹤0.01% 1138
2025
Q4 		$74.1K Buy
+15,180
New +$77.6K 0.01% 1216
2020
Q2 		– Sell
-367
Closed -$2K – 2162
2020
Q1 		$2K Hold
367
– – ﹤0.01% 1314
2019
Q4 		$4K Buy
+367
New +$3.27K ﹤0.01% 1789

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Cornerstone Capital Palo Alto, California $1B AUM 21.47% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Prelude Capital Management's NEPH Position: Q1 2026 in Review

Prelude Capital Management reduced its Nephros (NEPH) stake by 9.9% in Q1 2026, selling an estimated $5.99K and leaving 13,680 shares worth $40.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1138.

Prelude Capital Management first reported a position in NEPH in Q4 2019 and has held it in 4 quarters since. The position peaked at $74.1K in Q4 2025. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

  • Prelude Capital Management held 13,680 shares of Nephros worth $40.8K as of Q1 2026.
  • Prelude Capital Management sold 1,500 Nephros shares in Q1 2026, an estimated $5.99K.
  • Nephros made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1138 holding.
  • Prelude Capital Management first reported a position in Nephros in Q4 2019 and has held it in 4 quarters since.
  • Prelude Capital Management's Nephros position peaked at $74.1K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.